Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention

Sponsor
I.M. Sechenov First Moscow State Medical University
Study ID
NCT04778787
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of renal function in acute decompensation of chronic heart failure (ADHF) compared to standard therapy will be analyzed. Based on the dynamics of the clinical condition, the duration of hospitalization, and blood biochemical parameters (creatinine, urea, uric acid, potassium, sodium, N-terminal pro-brain natriuretic peptide - NT-proBNP) conclusions will be drawn about the possibility of using SGLT2i in this group of patients.

Key Dates

Start date
Jan 1, 2021
Status verified
Mar 2022
Primary completion
Aug 1, 2022
Completion
Aug 1, 2022

Study Design

Enrollment
370 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: the intervention group
    The intervention group includes patients with decompensated chronic heart failure. The diagnosis will be made according to the criteria described above
  • Experimental: the control group
    The control group will be identical to the main group.

Primary Outcome Measure

death due to heart failure [ Time Frame: through study completion, an average of 5 days ]

Related Studies